All In Biotech

Drug Trial Radar · NCT06668181

An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

Open-Label, Single-Arm Trial to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants From 2 to Less Than 18 Years of Age With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-Related Arthritis (Including Juvenile-Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Mar 11, 2025

Primary completion

Apr 12, 2028

Study completion Jul 31, 2030

Sponsor

Lead sponsor
UCB Biopharma SRLUCB
Sponsor type
Industry
First posted
Oct 31, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess plasma bimekizumab concentrations following subcutaneous (sc) bimekizumab administration.

Conditions

  • Enthesitis-related Arthritis
  • Juvenile Psoriatic Arthritis

Interventions

  • BimekizumabDrug

    Bimekizumab will be administered at pre-specified timepoints.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Plasma bimekizumab concentrations over the Initial Treatment PeriodTime frame: Up to Week 16

Locations

23 sites in 6 countries. Site status is shown where the registry gives one.

  • Ja0005 50646

    Calgary, Canada · Recruiting

  • Ja0005 50644

    Montreal, Canada · Recruiting

  • Ja0005 50645

    Saskatoon, Canada · Recruiting

  • Ja0005 40777

    Indre-et-Loire, France · Recruiting

  • Ja0005 40510

    Le Kremlin-Bicêtre, France · Recruiting

  • Ja0005 40778

    Paris, France · Recruiting

  • Ja0005 40776

    Poitiers, France · Recruiting

  • Ja0005 40369

    Berlin, Germany · Recruiting

  • Ja0005 40356

    Dresden, Germany · Recruiting

  • Ja0005 40072

    Freiburg im Breisgau, Germany · Recruiting

  • Ja0005 40852

    Hamburg, Germany · Recruiting

  • Ja0005 40787

    Sankt Augustin, Germany · Recruiting

  • Ja0005 40779

    Sendenhorst, Germany · Recruiting

  • Ja0005 40427

    Tübingen, Germany · Recruiting

  • Ja0005 40720

    Krakow, Poland · Withdrawn

  • Ja0005 40780

    Sosnowiec, Poland · Recruiting

  • Ja0005 40781

    Esplugues de Llobregat, Spain · Recruiting

  • Ja0005 40100

    Madrid, Spain · Recruiting

  • Ja0005 40782

    Valencia, Spain · Recruiting

  • Ja0005 40786

    Bristol, United Kingdom · Recruiting

  • Ja0005 40783

    Manchester, United Kingdom · Recruiting

  • Ja0005 40785

    Nottingham, United Kingdom · Recruiting

  • Ja0005 40784

    Stoke-on-Trent, United Kingdom · Completed

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.